{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:13:35Z","timestamp":1790882015689,"version":"4.1.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7,1]]},"DOI":"10.1210\/jc.2009-0154","type":"journal-article","created":{"date-parts":[[2009,4,28]],"date-time":"2009-04-28T21:13:39Z","timestamp":1240953219000},"page":"2495-2501","source":"Crossref","is-referenced-by-count":66,"title":["Effects of Teriparatide Retreatment in Osteoporotic Men and Women"],"prefix":"10.1210","volume":"94","author":[{"given":"Joel S.","family":"Finkelstein","sequence":"first","affiliation":[{"name":"Endocrine Unit, Department of Medicine (J.S.F., J.J.W., B.Z.L., S.M.B., H.J., R.M.N.), Massachusetts General Hospital, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Wyland","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Medicine (J.S.F., J.J.W., B.Z.L., S.M.B., H.J., R.M.N.), Massachusetts General Hospital, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Z.","family":"Leder","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Medicine (J.S.F., J.J.W., B.Z.L., S.M.B., H.J., R.M.N.), Massachusetts General Hospital, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri-Ann M.","family":"Burnett-Bowie","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Medicine (J.S.F., J.J.W., B.Z.L., S.M.B., H.J., R.M.N.), Massachusetts General Hospital, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lee","sequence":"additional","affiliation":[{"name":"Biostatistics Center (H.L.), Massachusetts General Hospital, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Ju\u0308ppner","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Medicine (J.S.F., J.J.W., B.Z.L., S.M.B., H.J., R.M.N.), Massachusetts General Hospital, Boston, Massachusetts 02114"},{"name":"Pediatric Nephrology Unit, Department of Pediatrics (H.J.), Massachusetts General Hospital, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Neer","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Medicine (J.S.F., J.J.W., B.Z.L., S.M.B., H.J., R.M.N.), Massachusetts General Hospital, Boston, Massachusetts 02114"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113542401700_R1","first-page":"1366","article-title":"Osteoporosis","author":"Finkelstein","year":"2000","journal-title":"In: Goldman L, Bennett JC, eds. Cecil textbook of medicine. 21st ed. Philadelphia: W.B. Saunders Company;"},{"key":"key\n\t\t\t\t2019041113542401700_R2","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199412153312404","article-title":"Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.","volume":"331","author":"Finkelstein","year":"1994","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113542401700_R3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jama.280.12.1067","article-title":"Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1\u201334): a randomized, controlled trial.","volume":"280","author":"Finkelstein","year":"1998","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113542401700_R4","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis.","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113542401700_R5","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113542401700_R6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113542401700_R7","first-page":"3069","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.","volume":"85","author":"Kurland","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113542401700_R8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis.","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113542401700_R9","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1\u201334)] with alendronate in postmenopausal women with osteoporosis.","volume":"87","author":"Body","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113542401700_R10","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.","volume":"20","author":"Chen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113542401700_R11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate.","volume":"353","author":"Cosman","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113542401700_R12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113542401700_R13","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/jc.2006-0190","article-title":"Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.","volume":"91","author":"Finkelstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113542401700_R14","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1172\/JCI116273","article-title":"An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.","volume":"91","author":"Hodsman","year":"1993","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019041113542401700_R15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113542401700_R16","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041113542401700_R17","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/endo.132.4.8462456","article-title":"The effect of recombinant human (1\u201384) or synthetic human (1\u201334) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats.","volume":"132","author":"Kimmel","year":"1993","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019041113542401700_R18","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/jbmr.5650061008","article-title":"Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone.","volume":"6","author":"Liu","year":"1991","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113542401700_R19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jbmr.5650070503","article-title":"Intermittent administration of bovine PTH-(1\u201334) increases serum 1,25-dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats.","volume":"7","author":"Mitlak","year":"1992","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113542401700_R20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1210\/endo.132.2.8425497","article-title":"Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats.","volume":"132","author":"Wronski","year":"1993","journal-title":"Endocrinology"},{"key":"key\n\t\t\t\t2019041113542401700_R21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis.","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113542401700_R22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1359\/JBMR.051020","article-title":"Effect of teriparatide [rhPTH(1\u201334)] on BMD when given to postmenopausal women receiving hormone replacement therapy.","volume":"21","author":"Ste-Marie","year":"2006","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113542401700_R23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/jbmr.5650020503","article-title":"Age-related rise in parathyroid hormone in man: the use of intact and midmolecule antisera to distinguish hormone secretion from retention.","volume":"2","author":"Young","year":"1987","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113542401700_R24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1359\/jbmr.1997.12.4.652","article-title":"Total body bone mineral density in young children: influence of head bone mineral density.","volume":"12","author":"Taylor","year":"1997","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113542401700_R25","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/BF01738113","article-title":"Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1\u201338)hPTH and diphosphonate EHDP.","volume":"66","author":"Hesch","year":"1988","journal-title":"Klin Wochenschr"},{"key":"key\n\t\t\t\t2019041113542401700_R26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0169-6009(90)90080-Y","article-title":"Biochemical responses to sequential human parathyroid hormone (1\u201338) and calcitonin in osteoporotic patients.","volume":"9","author":"Hodsman","year":"1990","journal-title":"Bone Miner"},{"key":"key\n\t\t\t\t2019041113542401700_R27","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/jbmr.5650110403","article-title":"Sequential effects of chronic human PTH (1\u201384) treatment of estrogen-deficiency osteopenia in the rat.","volume":"11","author":"Mitlak","year":"1996","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113542401700_R28","article-title":"Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.","author":"Lindsay","year":"16 2008","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113542401700_R29","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113542401700_R30","first-page":"1214","article-title":"Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis.","volume":"84","author":"Finkelstein","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113542401700_R31","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/7\/2495\/9065989\/jcem2495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T15:00:01Z","timestamp":1558278001000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/94\/7\/2495\/2597078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,1]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2009-0154","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,1]]}}}